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Esophageal adenocarcinoma has become more prevalent 
in the US, with a 16-fold increase over the course of the 
second half of the twentieth century. This pathology can 
be a devastating disease, with 5-year survival reported as 
low as 14%. When stratifying patients, the most important 
prognostic factors are preoperative clinical stage and 
the presence of nodal metastasis (Dolan). Because of the 
significant morbidity associated, interest in the development 
of appropriate treatment is certainly high. Resection has 
been the mainstay of treatment, but management choices 
have evolved, with continued discussion of the role of 
neoadjuvant therapy (chemotherapy or chemoradiotherapy), 
endoscopic interventions, and adjuvant therapy. Data 
conflict, but there is some consensus on the role of 
neoadjuvant chemoradiotherapy (CRT) followed by 
resection in T3 disease and N1 or greater disease (1). 
Treatment is grounded in the acceptance that pathologic 
complete response improves survival (2). 
In addition to the role of neoadjuvant therapy for 
locally advanced disease, general agreement exists on the 
effectiveness of resection for early stage T1 disease (the 
debate focusing on the appropriate role for endoscopic 
resection compared to surgical therapy). Clinical T2N0 
(cT2N0) disease, however, is a controversial subset of 
patients within the larger population of patients with 
esophageal cancer (1). T2 disease invades the muscularis 
propria of the esophagus, with potential infiltration into 
submucosal lymphatics, but is confined to the walls of 
the esophagus (1,3,4). It is, thus, considered to be an 
intermediate and therefore unpredictable tumor group. 
Taken as a whole, clinical T2N0 5-year survival hovers 
around 50% (4). The approach to cT2N0 disease becomes 
rather difficult, in no small part because clinical staging 
is often unreliable. Studies have shown that at time of 
resection, upstaging of cT2N0 patients is a fairly common 
occurrence. Our own 21-year institutional experience found a 
48.5% rate of understaging in patients who underwent surgery. 
This was more common in poorly differentiated tumors (5). 
This is supported by the literature, with other studies citing 
25–55% of these patients upstaged, and 35% found to have 
positive lymph nodes (6,7). This is not an insignificant 
finding, as the finding of positive nodes in this patient 
group led to poor survival (41% at 5-year follow-up) (6). 
Upstaging has been found to increase in frequency with 
poor differentiation, lymphovascular invasion and higher 
tumor size (over 3 cm) (8-10). 
Histology of carcinoma is another aspect of esophageal 
disease that must be explored. While adenocarcinoma is 
the most common type in the US and Western Europe, 
squamous cell carcinoma also makes up a portion of disease. 
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Squamous cell carcinoma has been found to have higher rates 
of pathologic complete response when patients are treated 
with adjuvant and neoadjuvant chemoradiotherapy (11). 
Differences in this patient group are present in origin cell 
type, but there are also differences in the epidemiology 
and, because the geography differs, health care systems 
differences in availability of care. Thus, discussion on the 
approach to cT2N0 disease cannot be generalized from 
adenocarcinoma to squamous cell carcinoma (8).
The controversy in treatment is multifold, and optimal 
treatment has yet to be defined (4). Part of the difficulty 
in the development of evidence-based recommendations 
is that prior randomized controlled trials have either been 
too limited in scope, had inaccurate preoperative staging, or 
lacked sufficient subgroup analysis (2). 
Staging
Despite a lack of clear guidelines for the treatment of this 
patient population, there are at least fairly standard accepted 
aspects of the preoperative testing of these patients. In order 
to stage before surgical resection, most patients undergo 
CT scan of the chest, abdomen, and pelvis, FDG-PET scan, 
and EUS evaluation (1). Each of these tests, while certainly 
crucial, carries with it some degree of error and, thus, the 
opportunity for contributing to error in staging. Accurate 
clinical staging directs care but is difficult to obtain, and 
pathological staging has been found to differ from clinical 
staging in as much as 90% of cases (5,9,12,13).
CT scanning is excellent for obtaining the largest amount 
of detail of the general state of the tumor. Specifically, depth 
of invasion can be evaluated through this modality, and 
nodal involvement assessed. Unfortunately, the accuracy of 
CT scanning for measurement of depth of invasion is cited 
as 50–80%, and nodal involvement is accurate in 50–70% 
(1,2). The value of FDG-PET is in the detection of radio 
uptake seen in malignant cells, with the goal of metastatic 
detection. The sensitivity and specificity of PET scanning for 
regional metastases, however, ranges from 57–85% (1,2). EUS 
allows for evaluation of depth of invasion, regional nodes, 
and lymphovascular invasion. Lymphovascular invasion is an 
area of interest because it is the only independent predictor 
of the presence of nodal involvement in a study of tumor 
variables (odds ratio 5.24) (6). EUS accuracy for the detection 
of regional nodes stands at 80%, and at 74–90% for the 
evaluation of T stage in all esophageal cancer patients, but 
the accuracy of T stage evaluation is lowest in T2 tumors, 
with accurate description of 31% (1). Interestingly, despite 
advances in the technology supporting each of these 
modalities, the accuracy of staging has not improved in 
recent years (14).
Treatment
When considering the treatment options for cT2N0 
disease, the main area of contention is on the role of 
neoadjuvant chemoradiotherapy prior to surgical resection. 
It should be briefly mentioned that endoscopic resection 
has been explored in one study in this patent group (15), 
reflecting the frequent overstaging of cT2N0 patients. This 
approach has not been adopted widely, and most cT2N0 
patients will receive more radical treatment.
The  vo lume of  s tud ies  examining  the  ro le  o f 
multimodality therapy is not as broad as that for other 
clinical stages. In our previously reported experience, 
we found that among patients who underwent induction 
therapy the pathologic complete response rate was 27.2%; 
patients who received this therapy were less likely to 
have lymph node metastasis at resection (12.1% vs. 40%) 
although long-term survival was similar (5). A recent 
systematic review of ten studies comparing neoadjuvant 
therapy with surgery alone in clinical T2N0 found no 
improvement in survival with neoadjuvant therapy, no 
difference in recurrence risk, no difference in anastomotic 
leak rates, and actually demonstrated a lower probability for 
R0 resection in patients who received induction therapy (4). 
Markar et al. examined a cohort of 2,944 patients with 
cT2N0 disease and found no survival benefit or decreased 
recurrence in patients who received neoadjuvant therapy. 
The only difference found was a greater rate of malnutrition 
in the patients receiving neoadjuvant therapy (21.4% 
vs. 9.8% in the surgery group). Nodal understaging was 
widespread, and this group had a median 1.7 positive lymph 
nodes at time of resection, with 48.1% understaged for 
nodal status, and 34.7% understaged for T status (7). The 
Esophageal Cancer Study Group examined data on clinical 
T2N0 patients from twenty-six high volume centers, 
fifteen of which contributed original data (14). They found 
a median survival of 57% at 5 years, without differences 
across patients receiving induction therapy and surgery. 
This was in the setting of pathologic complete response 
in 29% of patients receiving induction CRT. Staging was 
accurate in only 14% of patients, with 50% of patients 
understaged, including 39% who were found to be node-
positive. A review of all cT2N0 patients between 1998 and 
2011 in the National Cancer Database revealed similar 
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outcomes, with a similar survival in the group receiving 
esophagectomy alone and patients with induction therapy 
[41.1 vs. 41.9 months (16)]. Finally, specifically considering 
squamous cell carcinoma, Chen’s group found that patients 
who received neoadjuvant CRT were able to achieve 
pathologic complete response in 37% of cases. Still, this 
did not result in improved overall survival compared to 
surgery alone but did improve disease specific survival (85% 
at 5 years with pathologic complete response followed by 
esophagectomy (3).
Contrary to these studies, a study of 533 patients from 
the Netherlands Cancer Registry identified both a higher 
rate of radical resection and better long-term survival 
in the neoadjuvant group (17). It thus appears that the 
overwhelming majority of current literature, although 
retrospective, points towards a lack of clear benefit of 
neoadjuvant therapy in cT2N0 patients. This is especially 
important given that the use of CRT is not totally benign 
and could increase risk of postoperative complications 
(4,16,18).
The question of who receives neoadjuvant therapy was 
considered by Samson et al. (19). They considered factors 
associated with induction therapy. Higher education, 
receiving treatment at a community cancer center, and more 
recent diagnosis year all were associated with significantly 
higher rates of neoadjuvant treatment. The only factor they 
found to decrease likelihood was increased age. The results 
of this study certainly raise socioeconomic questions and are 
worthy of further consideration. 
The timing of neoadjuvant therapy prior to esophagectomy 
has also been explored. Qin et al. conducted a review 
of twelve studies, with a focus on if surgery conducted 
farther than 7 to 8 weeks after the completion of CRT 
had an impact on treatment (20). They found that 
in patients who received esophagectomy less than 
7 weeks after CRT had higher rates of pathologic complete 
response. Additionally, 30-day mortality was increased in 
patients who had a longer period between CRT and surgery. 
This result was explored further and found to be significant 
in the subgroup of patients with adenocarcinoma, while 
patients with squamous cell carcinoma had similar outcomes 
regardless of timing.
Conclusions
The approach to cT2N0 esophageal cancer is a complex 
and controversial one. Inconsistency in preoperative 
staging, flaws in diagnostic instruments, and absence of 
large randomized controlled trials lead to a dearth of clear 
guidelines for these patients. NCCN recommendations 
are upfront surgery with low-risk lesions, but CRT, 
chemotherapy, or definitive chemoradiation for all 
others (9), but these recommendations leave a great deal 
of discretion to individual providers. While the majority 
of studies have not demonstrated benefit to survival with 
CRT, subgroup analysis of understaged patients who receive 
treatment has not yet been adequately explored. With 
discordant staging, patients who are overstaged and thus 
overtreated are included with those patients whose nodal 
status in underpredicted, which could certainly bias results. 
Unfortunately, until a study with large enough subgroups to 
explore these effects is conducted, it is difficult to quantify 
these effects. Improving the accuracy of preoperative testing 
and consequently preoperative staging should be of the 
highest priority when considering the future direction of 
treatment for cT2N0 esophageal cancer, and multicenter 
studies of this patient population can provide the data 
necessary to make a meaningful recommendation for this 
patient group. 
At this point in time, recommendations should be that 
patients with cT2N0 esophageal cancer should undergo 
the most accurate pre-treatment staging possible before 
decision-making for the use of neoadjuvant therapy. It 
is also important to keep in mind the risk factors for 
upstaging as identified in several studies, including presence 
of lymphovascular invasion, poor tumor differentiation 
and tumor size >3 cm when deciding how to proceed 
with patient treatment. It seems reasonable to consider 
neoadjuvant therapy when one or more of these factors are 
present; as there is no set pathway for approach to cT2N0 
disease, each patient’s treatment algorithm will be somewhat 
unique, and it is up to the provider to make the choices that 
are best for each patient. 
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